Autoimmune Disease Treatment Industry - Regional Synopsis
North America Market Analysis
North America is anticipated to garner the highest revenue from the autoimmune disease treatment market, accounting for a 38.4% share, throughout the discussed period. The significantly high rate of incidence of associated ailments is the primary driver behind the region's leadership. In this regard, the NIH identified more than 23.6 million citizens of America as having autoimmune disorders. In addition, the number of new diagnoses across North America surpassed 8.5 million. This continuous demographic expansion represents a sustainable demand for advanced biologics and other related therapeutics, fostering a favorable trading atmosphere for both domestic and foreign biopharma developers and producers.
The U.S. is augmenting leadership in the regional autoimmune treatment market due to increased biologic adoption and a strong reimbursement structure. The country represents a progressive atmosphere with ongoing biological innovations and developed healthcare system, which can be testified by the magnifying R&D investments. For instance, in 2023, the research funding from the Federal government reached USD 5.1 billion. Simultaneously, Medicare coverage expanded by 15.3% from 2020 to 2024. Besides, in 2023, the acceleration in the process of FDA compliance broadened the range of products in this field with 14 new autoimmune medicines. Moreover, the emergence of biosimilars is evolving the dynamics in this marketplace.
APAC Market Statistics
Asia Pacific is projected to register the highest CAGR in the global autoimmune disease treatment market from 2025 to 2037. The region's propagation is predominantly pledged to infrastructural modernization, a rapidly aging population, and a strong emphasis on generic production. As evidence, the proportion of older citizens, aged 65 and over, in Japan is showing a possibility of acquiring 30.1% by 2030. Thus, the net spending on biologics in this country surpassed USD 3.4 billion, as per the Ministry of Health, Labour and Welfare. Moreover, with the focus on enhancing affordability, emerging landscapes such as China and India are establishing an influential impact on the economic output in this sector.
In 2024, the National Medical Products Administration in China recorded approximately 1.6 million yearly incidences of autoimmune ailments nationwide. As a response, the governing body of this country increased its expenditure on this category by 15.2% from 2019 to 2024. This reflects a sustainable demand and substantial capital influx in the China autoimmune disease treatment market. Furthermore, the country is ensuring continuous expansion and progress in this merchandise with enhanced insurance coverage and funding volume. For instance, in 2024, the Nation Healthcare Security Administration incorporated 7 additional biologics in their national reimbursement policy, which cut per-patient costs by 50.4%.
